ProKidney Up 26%, Insiders Still In The Red By US$35m
ProKidney Corp. - Class A Ordinary Shares PROK | 0.00 |
Insiders who bought US$54.7m worth of ProKidney Corp. (NASDAQ:PROK) stock in the last year have seen some of their losses recouped as the stock gained 26% last week. However, total losses seen by insiders are still US$35m since the time of purchase.
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
We've discovered 5 warning signs about ProKidney. View them for free.The Last 12 Months Of Insider Transactions At ProKidney
Over the last year, we can see that the biggest insider purchase was by Chairman of the Board Pablo Legorreta for US$55m worth of shares, at about US$2.42 per share. That means that an insider was happy to buy shares at above the current price of US$0.87. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. The only individual insider to buy over the last year was Pablo Legorreta.
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
ProKidney is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Insider Ownership
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. ProKidney insiders own about US$21m worth of shares. That equates to 9.7% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
So What Does This Data Suggest About ProKidney Insiders?
There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. Insiders do have a stake in ProKidney and their transactions don't cause us concern. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing ProKidney.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Recommend
- Simply Wall St 02/12 19:23
Cardio Diagnostics Announces Centers for Medicare and Medicaid Services Issued Final Gapfill Payment Rate Of $854 For Epi+Gen CHD And PrecisionCHD Tests
Benzinga News 03/12 13:37Why Agios Pharmaceuticals (AGIO) Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat
Simply Wall St 03/12 16:20Natera (NTRA): Valuation Check After ASH Signatera Lymphoma Data Fuels Hematology Growth Optimism
Simply Wall St 03/12 17:18Enanta Pharmaceuticals Officer Kathleen S. Capps Reports Sale of Common Shares
Reuters 03/12 22:09Praxis Precision Medicines (PRAX): Reassessing Valuation as AES Epilepsy Pipeline Data Draws Investor Focus
Simply Wall St Today 02:24Should New LEQEMBI Data and Subcutaneous Option Shift the Risk Profile for Biogen (BIIB) Investors?
Simply Wall St Today 07:18Estrella Immunopharma Advances EB103 T-Cell Therapy to Phase II After Positive Safety Review
Reuters 33m


